Please login to the form below

Not currently logged in
Email:
Password:

Promising Innovative Medicine

This page shows the latest Promising Innovative Medicine news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s first-in-class breast cancer therapy wins EU licence

Pfizer’s first-in-class breast cancer therapy wins EU licence

The European Commission has granted Pfizer's first-line breast cancer drug Ibrance marketing authorisation in Europe, making it the first new medicine to get to market in this setting in ... The first-in-class treatment was awarded Promising Innovative

Latest news

  • NICE 'no' for Opdivo in kidney cancer NICE 'no' for Opdivo in kidney cancer

    Johanna Mercier, general manager, Bristol-Myers Squibb UK &Ireland, said: “ Nivolumab is a game-changing medicine, which has been consistently recognised, in its approved indications, by the Medicines and Healthcare products ... Regulatory Agency (MHRA)

  • Novartis still hungry after absorbing GSK oncology Novartis still hungry after absorbing GSK oncology

    Jimenez is however already in the market for mid-scale acquisitions in the $2bn-$5bn range to bolster its three core units in innovative pharma, eyecare and generics. ... Early access for LCZ696. The Swiss drug major is celebrating another positive

  • Novartis cancer pill makes it onto UK early access list Novartis cancer pill makes it onto UK early access list

    The UK drugs regulator the MHRA has granted a 'promising innovative medicine' for its new lung cancer drug Zykadia (ceritinib). ... Specifically, the pill has been designated as a promising innovative medicine (PIM) for the treatment of patients with

  • Keytruda is UK's first early-access medicine Keytruda is UK's first early-access medicine

    Keytruda is UK's first early-access medicine. Merck’ s melanoma therapy accepted under the UK’ s EAMS. ... In January, BMS claimed Opdivo was the first PD-1 inhibitor to be awarded Promising Innovative Medicine (PIM) status - the first stage in the

  • BMS' Opdivo set for early access in UK BMS' Opdivo set for early access in UK

    The Medicines and Healthcare products Regulatory Agency (MHRA) has labelled PD-1 inhibitor Opdivo (nivolumab) a Promising Innovative Medicine (PIM), the first stage in the UK's Early Access to Medicines ... According to the regulator, the opinion "will

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Charting a course for expansion Charting a course for expansion

    Cabometyx accelerates. Earlier this year Ipsen signed another deal to bolster its pipeline by harnessing external innovation, licensing promising cancer drug Cabometyx (cabozantinib) from Californian biotech Exelixis. ... Along the way it also received a

  • Creating a 21st century life sciences ecosystem Creating a 21st century life sciences ecosystem

    Part of the scheme involves a new 'promising innovative medicine' designation - similar to the FDA's breakthrough designation - the first of which have started to be awarded. ... Date Issued. Promising Innovative Medicine Designations. Details. September

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics